Holen Sie sich die Stockscreener-App
3.43
1.48%
0.05
Vorhandelsmarkt:
3.43
Turn Therapeutics Inc Aktie (TTRX) Neueste Nachrichten
Bradley Burnam holds 52.76% of Turn Therapeutics (NASDAQ: TTRX) common stock - Stock Titan
Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX) - Defense World
Athersys and Turn Therapeutics Battle for Biotech Supremacy - National Today
Turn Therapeutics (TTRX) CEO-linked entity gifts 300,000 shares, retains 15.7M - Stock Titan
Director at Turn Therapeutics (TTRX) makes bona fide gift of 300,000 shares - Stock Titan
Turn Therapeutics (TTRX) CEO receives 160,000 stock options at $3.43 strike - Stock Titan
80K options granted at $3.12 to Turn Therapeutics (TTRX) - Stock Titan
[EFFECT] Turn Therapeutics Inc. SEC Filing - Stock Titan
TTRX Stock Price, Quote & Chart | TURN THERAPEUTICS INC (NASDAQ:TTRX) - ChartMill
Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results - MarketBeat
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - BioSpace
Turn Therapeutics (TTRX) registers up to 7,000,000 shares for GEM resale - Stock Titan
Turn Therapeutics (TTRX) registers 17.87M shares for resale by stockholders - Stock Titan
Turn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Turn Therapeutics (TTRX) details eczema drug plans and going-concern risk - Stock Titan
Turn Therapeutics (NASDAQ: TTRX) widens 2025 loss but secures $25M growth capital - Stock Titan
Turn Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
TTRX SEC FilingsTurn Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart
Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN
D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX) - MarketBeat
TTRX Maintains 'Buy' Rating with $8.00 Price TargetLatest Ana - GuruFocus
Turn Therapeutics Secures Growth Capital to Advance Dermatology - tipranks.com
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com
Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView — Track All Markets
Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan
Turn Therapeutics Inc. Enters into Loan and Security Agreement for Up to $25 Million Growth Capital Loan Facility with Avenue Venture Opportunities Fund Ii, L.P - MarketScreener
Turn Therapeutics secures $25M loan facility from Avenue Capital By Investing.com - Investing.com Canada
Turn Therapeutics secures $25M loan facility from Avenue Capital - Investing.com
Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com
Turn Therapeutics Inc. (TTRX) - Minichart
Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - MarketScreener
Turn Therapeutics Inc. (TTRX) AI-Powered Stock Analysis - Meyka
Turn Therapeutics Inc. (TTRX) Stock forecasts - Yahoo Finance UK
Turn Therapeutics (TTRX) Stock Forecast and Price Target 2026 $TTRX - MarketBeat
Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX) - Defense World
Turn Therapeutics (TTRX) Stock Analysis Report | Financials & Insights - Benzinga España
TTRX: Phase II eczema trial for a novel IL-36/IL-31 inhibitor expects key data in Q2 2026 - TradingView
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy - MarketBeat
TTRX: Lead topical for eczema in phase II, with phase III trials planned and strong safety data - TradingView
Atara jumps amid report on FDA’s U-turn on cell therapy - Seeking Alpha
Technical Analysis of Turn Therapeutics Inc. (NASDAQ:TTRX) - TradingView
Turn Therapeutics Appoints Robert Redfield as Senior Advisor - TipRanks
Turn appoints Dr. Robert Redfield as senior advisor to guide GX-03 regulatory and clinical strategy - TradingView
Former CDC director joins Turn Therapeutics (TTRX) as senior health policy advisor - Stock Titan
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs - Caledonian Record
How much upside does Compass Therapeutics Inc. haveWall Street Watch & Daily Stock Momentum Reports - mfd.ru
What is the next catalyst for Palvella Therapeutics Inc.July 2025 Spike Watch & Consistent Return Investment Signals - mfd.ru
TTRX Should I Buy - Intellectia AI
Turn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Will Ovid Therapeutics Inc. announce a stock splitQuarterly Market Review & Detailed Earnings Play Strategies - mfd.ru
Can Xilio Therapeutics Inc. expand into new marketsDollar Strength & Entry Point Confirmation Signals - mfd.ru
Aug Sentiment: What is the fair value of Candel Therapeutics Inc. stock nowJuly 2025 Reactions & Weekly Top Stock Performers List - mfd.ru
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences - BioSpace
Turn Therapeutics Highlights GX-03 Progress at Investor Conferences - TipRanks
Turn Therapeutics Inc Announces Presentations at Healthcare Conferences - TradingView
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):